We’re seeking exceptional postdoctoral researchers to pioneer therapies for Alzheimer’s and other dementias.
- PRECISION SMALL-MOLECULE THERAPEUTICS
Precision small molecules against Alzheimer’s disease.
Ultimate Medicine designs first-in-class small molecules that block the enzyme driving cognitive decline — targeting the biochemistry of the disease at its origin.
- 01 - THE SCIENCE
An overlooked driver of Alzheimer's disease - a microbially produced effector, switched off by precision chemistry.
At Ultimate Medicine, we are advancing a new class of first-in-class small molecules that block the enzyme behind cognitive decline, stopping the disease before it begins
A new class of therapeutics targeting BM01
Our small molecules selectively inhibit the bacterial enzyme that produces BM01 - preventing the effector from ever reaching the concentration that drives disease.
02 — THE MiDE FRAMEWORK
From a general principle to a precision therapy for Alzheimer's.
MiDE — the Microbiome-Derived Effector framework — describes how a molecule made by gut bacteria can become a biochemical driver of disease. We follow that logic from its broadest form down to a single, addressable target in Alzheimer's.
Microbes make effectors
Bacteria in the gut produce small effector molecules that enter circulation and signal throughout the body.
Effectors become drivers
Above a critical concentration, an effector stops being benign and begins to actively drive disease biology.
BM01 drives cognitive decline
In Alzheimer's, the effector is BM01. We block the enzyme that makes it — holding BM01 below threshold.
MECHANISM
Keep BM01 below the threshold, and cognition is protected.
Cognitive decline begins once circulating BM01 crosses a critical threshold. Our small molecules inhibit its biosynthesis — holding levels in the safe range over time.
03 — PLATFORM
One enzymatic target. A platform with reach across neurological disease - starting with Alzheimer's.
— 04 - TEAM
Join who?
— 05 - ADVISORY
The people building Ultimate Medicine — drug hunters, biochemists and clinicians turning the MiDE framework into medicine.
UM Science Advisory Board
UM Advisory Board
-
SAB CHAIR
Veteran biopharma executive and serial board member with 35+ years advancing blockbuster therapeutics and shaping drug discovery strategy across pharma, biotech, and venture-backed companies.ription text goes here -
Global Alzheimer’s research leader and ADNI founder whose biomarker and imaging frameworks underpin the majority of modern AD clinical trials and regulatory decisions.escription text goes here
-
Distinguished medicinal chemist and Head of Drug Discovery at ZHAW with 25+ years of Big Pharma and academic experience, securing €15M+ in competitive funding across antiviral, antimicrobial, and oncology programs.Description text goes here
-
SCIENCE ADVISOR
Former Global Head of Neuroscience Discovery at Roche and seasoned board-level advisor with decades of experience advancing Alzheimer’s therapeutics from discovery through late-stage clinical development.
-
Co-discoverer of novel metabolic pathways underlying neurodegeneration, forming the scientific basis for Ultimate Medicine’s small-molecule strategy to block toxic metabolite synthesis and restore neuronal function.
-
BOARD ADVISOR
Visionary physician-leader and former CEO of the Cystic Fibrosis Foundation who enabled 12 FDA-approved therapies and pioneered the venture-philanthropy model for drug development. -
BOARD ADVISOR
Seasoned biotech entrepreneur with 30+ years leading rare-disease companies from inception to market, including award-winning device development and successful venture-philanthropy partnerships.
Our Partners
